We are live on !
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter Est. Return
+26.71%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$624M
AUM Growth
+$131M
(+26%)
Cap. Flow
+$40.1M
Cap. Flow % of AUM
Cap. Flow %
6.42%
Top 10 Holdings %
Top 10 Hldgs %
81.94%
Holding
58
New
13
Increased
11
Reduced
7
Closed
13
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.7
years
Top 20 Avg Time Held
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mobia Medical
MOBI
|
+$10.3M |
| 2 |
Senseonics Holdings Inc
SENS
|
+$10.3M |
| 3 |
CG Oncology
CGON
|
+$7.19M |
| 4 |
Enliven Therapeutics
ELVN
|
+$6.37M |
| 5 |
Jade Biosciences
JBIO
|
+$6.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$8.33M |
| 2 |
Vir Biotechnology
VIR
|
+$4.1M |
| 3 |
Medtronic
MDT
|
+$2.42M |
| 4 |
Centene
CNC
|
+$2.29M |
| 5 |
Natera
NTRA
|
+$1.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Consumer Staples | 0.17% |
| 3 | Consumer Discretionary | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Dianthus Therapeutics
DNTH
$4.03B
| $205M | 32.85% |
2,104,184
| – | – |
2023 Q3
11 quarters
|
|
|
2
CG Oncology
CGON
$5.31B
| $99.4M | 15.92% |
1,398,948
+110,000
| +9% | +$7.19M |
2024 Q1
9 quarters
|
|
3
Oruka Therapeutics
ORKA
$4.76B
| $72.4M | 11.59% |
760,424
| – | – |
2024 Q2
8 quarters
|
|
|
4
Jade Biosciences
JBIO
$857M
| $37.8M | 6.05% |
1,700,708
+300,000
| +21% | +$6.26M |
2025 Q2
4 quarters
|
|
|
5
Enliven Therapeutics
ELVN
$2.73B
| $27.9M | 4.47% |
550,000
+150,000
| +38% | +$6.37M |
2025 Q1
5 quarters
|
|
6
Perspective Therapeutics
CATX
$248M
| $21.5M | 3.44% |
6,299,999
+250,000
| +4% | +$944K |
2024 Q2
8 quarters
|
|
7
Aktis Oncology
AKTS
$838M
| $15.6M | 2.5% |
484,200
+15,634
| +3% | +$321K |
2026 Q1
1 quarter
|
|
8
Palvella Therapeutics
PVLA
$1.73B
| $10.7M | 1.71% |
70,000
| – | – |
2025 Q4
2 quarters
|
|
|
9
Mobia Medical
MOBI
$269M
| $10.7M | 1.71% |
+798,282
| New | +$10.3M |
2026 Q2
0 quarters
|
|
10
Repligen
RGEN
$11.1B
| $10.6M | 1.7% |
77,800
| – | – |
2025 Q2
4 quarters
|
|
11
Immunic
IMUX
$95.1M
| $10.3M | 1.65% |
669,941
| – | – |
2024 Q1
9 quarters
|
|
|
12
Senseonics Holdings Inc
SENS
$411M
| $9.09M | 1.46% |
+1,600,000
| New | +$10.3M |
2026 Q2
0 quarters
|
|
13
Karyopharm Therapeutics
KPTI
$8.85M
| $9.03M | 1.45% |
924,487
+460,746
| +99% | +$4M |
2022 Q4
14 quarters
|
|
|
14
Teva Pharmaceutical Industries Limited
TEVA
$48.4B
| $6.78M | 1.09% |
200,000
-250,100
| -56% | -$8.33M |
2025 Q1
5 quarters
|
|
15
DexCom
DXCM
$32.5B
| $6.74M | 1.08% |
100,000
+10,000
| +11% | +$666K |
2026 Q1
1 quarter
|
|
16
Tempus AI
TEM
$11.8B
| $6.08M | 0.97% |
105,000
+80,000
| +320% | +$4.01M |
2026 Q1
1 quarter
|
|
|
17
Medtronic
MDT
$121B
| $5.48M | 0.88% |
70,000
-30,000
| -30% | -$2.42M |
2025 Q3
3 quarters
|
|
|
18
Vir Biotechnology
VIR
$1.69B
| $5.29M | 0.85% |
519,300
-430,700
| -45% | -$4.1M |
2026 Q1
1 quarter
|
|
19
Structure Therapeutics
GPCR
$1.5B
| $5.26M | 0.84% |
98,000
+68,000
| +227% | +$3.01M |
2026 Q1
1 quarter
|
|
20
Encompass Health
EHC
$12.6B
| $4.25M | 0.68% |
42,000
| – | – |
2025 Q2
4 quarters
|
|
21
Tenax Therapeutics
TENX
$50.9M
| $3.87M | 0.62% |
265,934
+50,000
| +23% | +$639K |
2026 Q1
1 quarter
|
|
22
Nuvectis Pharma
NVCT
$607M
| $3.68M | 0.59% |
+200,000
| New | +$2.24M |
2026 Q2
0 quarters
|
|
23
Insulet
PODD
$9.8B
| $3.65M | 0.59% |
+24,000
| New | +$4M |
2026 Q2
0 quarters
|
|
24
Boston Scientific
BSX
$64.3B
| $3.41M | 0.55% |
80,000
+20,000
| +33% | +$1.09M |
2022 Q1
17 quarters
|
|
25
Satellos Bioscience
MSLE
$137M
| $3.01M | 0.48% |
387,769
| – | – |
2026 Q1
1 quarter
|
|
Similar funds
BVC
Avidity Partners Management's Q2 2026 Portfolio in Review
As of Q2 2026, Avidity Partners Management held 58 positions worth $624M, up 26% from $494M the previous quarter. Its ten largest holdings account for 82% of the portfolio.
Avidity Partners Management deployed $40.1M of net new capital in Q2 2026, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Mobia Medical: 798,282 shares worth $10.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $8.33M trimmed.
- Avidity Partners Management's largest Q2 2026 buy was Mobia Medical: 798,282 shares worth $10.7M.
- Avidity Partners Management added most to CG Oncology in Q2 2026, an estimated $7.19M increase.
- Avidity Partners Management's biggest Q2 2026 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $8.33M.
- Avidity Partners Management fully exited Centene in Q2 2026, selling an estimated $2.29M.
- Avidity Partners Management's ten largest holdings make up 82% of its $624M portfolio in Q2 2026.
- Avidity Partners Management opened 13 new positions and closed 13 in Q2 2026.
- Avidity Partners Management's portfolio value rose 26% quarter-over-quarter to $624M.
Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.